Shanghai, China, Wednesday June 6, 2012: Hutchison MediPharma Limited (“HMP”) today announces that Phase I clinical data for Sulfatinib (HMPL-012) and Fruquintinib (HMPL-013), two of the novel small molecule targeted anti-cancer drugs of HMP, was presented at the 2012 American Society of Clinical Oncology (“ASCO”) Annual Meeting held in Chicago, Illinois, USA on Monday, 4 June 2012.
ASCO is a non-profit organization founded in 1964 with the goals of improving cancer care and prevention. Nearly 30,000 oncology practitioners belong to ASCO, representing all oncology disciplines and subspecialties. Members include physicians and health-care professionals in all levels of the practice of oncology. The ASCO Annual Meeting brings these people together to find cutting-edge scientific presentations and comprehensive educational content.
The Sulfatinib Phase I study enrolled and treated 43 patients with the drug given once or twice daily. Sulfatinib was well tolerated at doses up to 300mg per day or 150mg twice daily and demonstrated preliminary anti-tumor activity in multiple cancer types, including liver cancer. To date the Fruquintinib Phase I study had enrolled and treated 29 patients in six different dose cohorts. Fruquintinib was well tolerated at doses up to 4mg once daily and demonstrated excellent pharmacokinetic properties. Encouraging clinical activity including partial response was observed in colorectal, lung and gastric cancer. Fruquintinib 4mg once daily was determined as the recommended Phase II dose and appeared to be both safe and effective. The company believes that further clinical development of such regimen is warranted.
The two clinical data posters were presented during the “Developmental Therapeutics – Experimental Therapeutics” general poster session on Monday, 4 June 2012. Further information about the 2012 ASCO Annual Meeting and the abstracts is available at http://chicago2012.asco.org.
About VEGF/VEGFR Inhibitors
At an advanced stage, tumors secrete large amounts of vascular endothelial growth factor (“VEGF”), a protein, to stimulate formation of excessive vasculature (angiogenesis) around the tumor in order to provide greater blood flow, oxygen, and nutrients to the tumor. Vascular endothelial growth factor receptor (“VEGFR”) inhibitors stop the growth of veins around the tumor and thereby starve the tumor of the nutrients it needs to grow rapidly.
About Sulfatinib and Fruquintinib
Sulfatinib (HMPL-012) is a novel small molecule that selectively inhibits the tyrosine kinase activity associated with VEGFR and fibroblast growth factor receptors (“FGFR”). Pre-clinical data shows that Sulfatinib has demonstrated a narrow kinase inhibition profile, affecting mainly VEGFR and FGFR1, and consequently has an attractive anti-tumor profile. This compound is a potent suppressor of angiogenesis and exhibits higher potency as compared to approved VEGF drugs. It targets major cancer types such as hepatocellular carcinoma, colorectal cancer and breast cancer.
Fruquintinib (HMPL-013) is a novel small molecule compound that is highly selective in inhibiting certain VEGF receptors, namely VEGFR1, VEGFR2, and VEGFR3, and consequently has an attractive anti-tumor profile. Fruquintinib has shown highly potent inhibitory effects on multiple human tumor xenografts, including some refractory tumors such as pancreatic cancer and melanoma and anti-tumor and anti-angiogenic effect compares favorably to approved VEGF drugs.
HMP is a novel drug R&D company focusing on discovering, developing and commercializing innovative therapeutics in oncology and autoimmune diseases. With a team of around 200 scientists and staff, its pipeline is comprised of novel oral compounds for cancer and inflammation in development in North America, Europe, Australia and Greater China.